Enter Note Done
Go to previous page in this tab
Session
  • Presentation | ASH Poster Walk on New Developments in Targeted Therapies for Myeloid Malignancies Hosted by Blood Neoplasia
  • Scientific Program
  • Bookmark Icon
  • ODYSSEY: A First-in-Human Study of the Aldehyde Dehydrogenase (ALDH) Inhibitor ABD-3001 in Patients with Refractory/Relapsed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrom...
  • Schedule
    Notes
  • Set Timezone
  •  
    Route Me

Generic 'disconnected' Message
ASH Poster Walks

Full Paper Title: ODYSSEY: A First-in-Human Study of the Aldehyde Dehydrogenase (ALDH) Inhibitor ABD-3001 in Patients with Refractory/Relapsed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Heiblig:

Disclosure:
No relevant conflicts of interest to declare.

Co-Authors:
CME Status
Program
Main Session